RxDoctor Payments Data

Jason Rodriguez, MD

Clinical Cardiac Electrophysiology · Fort Wayne, INNPI 1093078339

Payments from drug & device makers

What this record shows

The money is spread across several categories — grants (55.4%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Medtronic at 38.9% of the total. Reporting peaked in 2019 at $20,064 and has fallen 84.8% since, to $3,053 in 2025.

$33,238in general payments, 2019–2025

Across 268 payments — averaging $124.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$13K
  • Boston Scientific$9K
  • Cardiofocus, Inc.$6K
  • Abbott$4K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$284
  • Impulse Dynamics (USA) Inc.$277
  • plus $1K from 19 others

What the payments were for

  • Grants$18,40155%
  • Travel & lodging$7,42022%
  • Food & beverage$7,28222%
  • Education$1340%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$33,238 in reported general payments places this provider in the 70th percentile of 72 clinical cardiac electrophysiology providers in Indiana.

See all clinical cardiac electrophysiology providers in Indiana

Medicare billing

Part B allowed, 2024
$241,102
Medicare patients
718
Services billed
2,917

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban293$358,701
XareltoRivaroxaban89$106,487
EntrestoSacubitril/Valsartan17$18,370
Dofetilide13$4,265
Metoprolol Succinate311$3,971
SotalolSotalol Hcl105$2,255
Amiodarone Hcl131$2,102
Flecainide Acetate59$1,456
Diltiazem 24hr Er (Cd)Diltiazem Hcl60$1,322
Midodrine Hcl25$804
Carvedilol86$747
Amlodipine Besylate78$482
Atorvastatin Calcium59$462
Hydralazine Hcl11$438
Rosuvastatin Calcium26$326

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$74$358,701293 claims
Johnson & JohnsonXarelto$130$106,48789 claims
NovartisEntresto$126$18,37017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 72 clinical cardiac electrophysiology providers in Indiana.

Other clinical cardiac electrophysiology in Fort Wayne

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →